Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
NCT01633112 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2019-05-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow recruitment” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-04-20Phase 3 first posted: Novartis Pharmaceuticals, Ofatumumab (NCT04353492)
- 2020-03-02Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (NCT01705236)
- 2019-11-25Phase 3 first posted: Everstar Therapeutics Limited, Etrasimod + Placebo (NCT04176588)
- 2019-11-21Phase 3 first posted: Pfizer, Etrasimod + Etrasimod (NCT04173273)
- 2019-11-07Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (NCT01201356)
- 2019-10-31Also stopped (terminated): Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Fingolimod + Dimethyl Fumarate (NCT03345940)
- 2019-10-25Phase 3 first posted: Celgene, RPC-1063 (NCT04140305)
- 2019-09-30Results posted on the registry: Novartis Pharmaceuticals, Fingolimod 0.5 mg (NCT02373098)
- 2019-09-23Results posted on the registry: Novartis Pharmaceuticals, FTY720 (NCT01585298)
- 2019-06-24Phase 3 first posted: Arena Pharmaceuticals, Etrasimod + Placebo (NCT03996369)
- 2019-05-15Phase 3 first posted: Pfizer, Etrasimod (NCT03950232)
- 2019-05-14Results posted on the registry: Isfahan University of Medical Sciences, Fingolimod + Placebo (for Fish Oil) (NCT02939079)
- 2019-05-10Phase 3 first posted: Arena Pharmaceuticals, Etrasimod + Placebo (NCT03945188)
- 2019-04-16Phase 3 first posted: Celgene, Ozanimod (NCT03915769)
- 2019-04-16Results posted on the registry: Indiana University, Fingolimod + placebo (NCT01779700)
- 2019-02-27Results posted on the registry: Novartis Pharmaceuticals, 0,5 mg Fingolimod (NCT02575365)
- 2019-02-27Also stopped (terminated): Novartis Pharmaceuticals, 0,5 mg Fingolimod (NCT02575365)
- 2019-02-08Results posted on the registry: Novartis Pharmaceuticals, fingolimod (NCT02720107)
- 2019-01-25Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (FTY720) (NCT01498887)
- 2018-09-19Results posted on the registry: Novartis Pharmaceuticals, Interferon beta-1a + Fingolimod (NCT01892722)
- 2018-08-09Phase 3 first posted: Novartis Pharmaceuticals, Siponimod (NCT03623243)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision